Select Page

Antiretroviral therapy in HIV/HCV coinfection: which role do integrase inhibitors play?

Antiretroviral therapy in HIV/HCV coinfection: which role do integrase inhibitors play?

SplashPage_DrRockstroh_En

Welcome to the Clinique médicale l’Actuel’s JOURNAL CLUB.
For more than 20 years, the Clinique médicale l’Actuel under the medical direction of Dr. Réjean Thomas, has been bringing together healthcare professionals, with a focus in virology, to learn from guest experts and discuss the most relevant clinical practice challenges facing them today.

[hr]

In this program, Dr. Marc Poliquin sits down with Dr. Jürgen Rockstroh from Bonn University, Germany, to discuss antiretrovirals in the treatment of HIV and hepatitis C coinfection and the role that integrate inhibitors play in their treatment.

Dr. Rockstroh further explains how to treat these co-infected patients and the role that the host of new drugs now used in combination to cure patients with hepatitis C also play.

Publish Date: May 5, 2014
[hr]

This activity is supported by an educational grant from:

[hr]

PROGRAM HIGHLIGHTS

[bullet_list icon=”check” indent=”10px” style=””]

  • Coinfection vs. monoinfection in the treatment of hepatitis C
  • Impact of ART on liver fibrosis and hepatitis C progression rates in patients coinfected with HIV and hepatitis C
  • Different treatments available, their combinations and what the future looks like[/bullet_list]
  • [hr]

[hr]

FACULTY

[toggle title=”VIEW FACULTY DISCLOSURE / CONFLICT OF INTEREST”]

ViroChannel has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

[hr] Marc Poliquin, MD has a financial interest/relationship or affiliation in the form of: Consultant: AbbVie, Bristol-Myers Squibb, Janssen, Gilead, Merck, ViiV Healthcare.

Jürgen K. Rockstroh, MD has a financial interest/relationship or affiliation in the form of: Consultant: Abbvie, Bionot, BMS, Boehringer Ingelheim, Gilead, GSK, Novartis, Pfizer, Roche, Tibotec, Tobira Therapeutics, ViiV Healthcare. [hr]

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses. No responsibility is taken for errors or omissions. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

[/toggle] [hr]

INTERVIEWER
Marc Poliquin, MD

Gastroenterologist and Hepatologist Verdun Hospital and Clinique médicale l’Actuel Montreal, Quebec, Canada

[hr]

INTERVIEWEE
Jürgen K. Rockstroh, MD

Professor of Medicine and Head of the HIV Outpatient Clinic University of Bonn Bonn, Germany            

 

Submit a Comment